Philip D Austin1, Ashley Craig2, James W Middleton2, Yvonne Tran3, Daniel S J Costa4,5,6,7,8, Paul J Wrigley4,5,8,9, Philip J Siddall10,6. 1. Department of Pain Management, HammondCare, Greenwich Hospital, Greenwich, Sydney, NSW, Australia. paustin@hammond.com.au. 2. John Walsh Centre for Rehabilitation Research, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Kolling Institute, Royal North Shore Hospital, St Leonards, NSW, Australia. 3. Centre of Healthcare Resilience and Implementation Science, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia. 4. Faculty of Medicine and Health, Pain Management Research Institute, The University of Sydney, Sydney, NSW, Australia. 5. Kolling Institute, Northern Sydney Local Health District, Sydney, NSW, Australia. 6. Sydney Medical School, University of Sydney, Sydney, NSW, Australia. 7. School of Psychology, University of Sydney, Sydney, NSW, Australia. 8. The University of Sydney, Sydney, NSW, Australia. 9. Michael J Cousins Pain Management and Research Centre, NSW Health, Royal North Shore Hospital, Sydney, NSW, Australia. 10. Department of Pain Management, HammondCare, Greenwich Hospital, Greenwich, Sydney, NSW, Australia.
Abstract
STUDY DESIGN: Within-subject, randomised cross-over trial. OBJECTIVES: To determine whether a commercially available 3D head-mounted (HMD) virtual reality (VR) device results in significant reductions in neuropathic pain compared to using a 2D screen device in people with spinal cord injury (SCI). SETTING: Greenwich Hospital, Sydney, Australia. METHODS:Sixteen men with established SCI and chronic neuropathic pain participated in a single-session randomised cross-over trial. We compared the effects of 3D HMD VR and a 2D screen application on SCI neuropathic pain intensity and levels of perceived presence. RESULTS: Participants reported significantly lower pain intensity after 3D HMD VR compared to 2D screen application (1.9 ± SD 1.8 versus 3.4 ± SD 1.6, mean 95% CI: 1.5, P < 0.0001). Participants reported significantly higher perceived levels of presence with the 3D HMD VR compared to 2D screen of (49.6 ± SD 8.9 versus 32.8 ± SD 11.1, mean 95% CI: 16.6, P < 0.0001). Increased perceived presence was associated with significantly lower pain intensity regardless of randomised sequencing of the two conditions (mean 95% CI: 0.06, P = 0.005). Effect size for pain reduction using 3D HMD VR was 0.80. CONCLUSIONS: We suggest that 3D HMD VR may provide neuropathic pain relief for people with SCI. Given the lack of cybersickness and ease of access, we propose that immersive VR could be a helpful adjunct to current pharmacotherapy. Further research is required to show that VR can be effective for more long-term reductions in SCI pain.
RCT Entities:
STUDY DESIGN: Within-subject, randomised cross-over trial. OBJECTIVES: To determine whether a commercially available 3D head-mounted (HMD) virtual reality (VR) device results in significant reductions in neuropathic pain compared to using a 2D screen device in people with spinal cord injury (SCI). SETTING: Greenwich Hospital, Sydney, Australia. METHODS: Sixteen men with established SCI and chronic neuropathic pain participated in a single-session randomised cross-over trial. We compared the effects of 3D HMD VR and a 2D screen application on SCI neuropathic pain intensity and levels of perceived presence. RESULTS:Participants reported significantly lower pain intensity after 3D HMD VR compared to 2D screen application (1.9 ± SD 1.8 versus 3.4 ± SD 1.6, mean 95% CI: 1.5, P < 0.0001). Participants reported significantly higher perceived levels of presence with the 3D HMD VR compared to 2D screen of (49.6 ± SD 8.9 versus 32.8 ± SD 11.1, mean 95% CI: 16.6, P < 0.0001). Increased perceived presence was associated with significantly lower pain intensity regardless of randomised sequencing of the two conditions (mean 95% CI: 0.06, P = 0.005). Effect size for pain reduction using 3D HMD VR was 0.80. CONCLUSIONS: We suggest that 3D HMD VR may provide neuropathic pain relief for people with SCI. Given the lack of cybersickness and ease of access, we propose that immersive VR could be a helpful adjunct to current pharmacotherapy. Further research is required to show that VR can be effective for more long-term reductions in SCI pain.
Authors: Nadine S Matthie; Nicholas A Giordano; Coretta M Jenerette; Gayenell S Magwood; Sharon L Leslie; Emily E Northey; Caitlin I Webster; Soumitri Sil Journal: Pain Manag Date: 2022-09-13
Authors: Graeme Mattison; Oliver Canfell; Doug Forrester; Chelsea Dobbins; Daniel Smith; Juha Töyräs; Clair Sullivan Journal: J Med Internet Res Date: 2022-07-01 Impact factor: 7.076
Authors: S Bonavita; L Lavorgna; G Abbadessa; F Brigo; M Clerico; S De Mercanti; F Trojsi; G Tedeschi Journal: J Neurol Date: 2021-05-20 Impact factor: 4.849
Authors: Yvonne Tran; Philip Austin; Charles Lo; Ashley Craig; James W Middleton; Paul J Wrigley; Philip Siddall Journal: Sensors (Basel) Date: 2022-03-29 Impact factor: 3.576